Understanding the role of Ph + ALL pathophysiology and BCR/ABL oncoprotein in leukemogenesis led to the discovery of the drug imatinib mesylate, a first-generation tyrosine kinase inhibitor (TKI). This evidence concerns the gene BCR and acute lymphoblastic leukemia.